ArticleRespiratory medicine case reports2026
Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report.
Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe pneumonia caused by methicillin-resistant Case presentation: We report the case of a 65-year-old woman with severe MRSA pneumonia, rapidly progressing to acute respiratory distress syndrome (ARDS) and apparently refractory to Linezolid and Ceftriaxone. Given the critical clinical condition, poor prognosis, and lack of alternative therapeutic options, off-label treatment with Oritavancin was initiated at a dose of 1200 mg IV infused over 3 h. Within 48 hours after administration, a marked improvement in gas exchange was observed, allowing extubation and progressive clinical recovery. Discussion: Oritavancin is a long-acting lipoglycopeptide approved for Gram-positive skin and soft tissue infections, but it demonstrates effective anti-MRSA activity in non-cutaneous sites as well. This case highlights its potential role as rescue therapy in selected settings such as respiratory infections caused by resistant pathogens refractory to standard therapy. Conclusion: In critical cases with failure of standard therapeutic options, Oritavancin may represent an effective and well-tolerated off-label option for the treatment of MRSA pneumonia refractory to conventional therapy, following multidisciplinary evaluation and informed consent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.